I-Myeloid Leukemia: Ukwelashwa Okusha Okusha

A BAMBA MahhalaRelease 2 | eTurboNews | eTN

I-Ascentage Pharma, inkampani yomhlaba wonke ye-biopharmaceutical ebambe iqhaza ekwakheni izindlela zokwelapha ezinomdlavuza, isifo sokusha kwesibindi kohlobo B (CHB), kanye nezifo ezihlobene nobudala, kanye ne-Innovent Biologics, Inc. (“Innovent”), inkampani esezingeni lomhlaba ye-biopharmaceutical eyakha, ekhiqizayo. futhi ihwebe ngemithi esezingeni eliphezulu yokwelapha i-oncology, i-metabolic, i-autoimmune nezinye izifo ezinkulu, ngokuhlanganyela bamemezela ukuthi ikhandidethi yesidakamizwa inoveli i-olverembatinib yase-Guangzhou HealthQuest Pharma Co., Ltd., Inc., inkampani ephethwe ngokuphelele ye-Ascentage Pharma, kugunyazwe i-China National Medical Products Administration (NMPA) yokwelashwa kweziguli ezikhulile ezine-tyrosine kinase inhibitor (TKI)-resistant phase chronic myeloid leukemia (CML-CP) noma i-accelerated-phase-phase CML (CML-AP) ephethe i-T315I ukuguqulwa kwezakhi zofuzo njengoba kuqinisekiswe ukuhlolwa kokuxilonga okuqinisekisiwe (inkomba engagunyazwanga e-US).

Ithuthukiswe yi-Ascentage Pharma ngosizo oluvela kuhlelo lweNational Major New Drug Discovery and Manufacturing, i-olverembatinib iyisidakamizwa esingaba sezingeni eliphezulu esizothengiswa ngokubambisana emakethe yaseChina yi-Innovent kanye ne-Ascentage Pharma, ukuze kuzuze iziguli eziningi imindeni. Njengoba isizukulwane sokuqala sesithathu sase-China i-BCL-ABL TKI ithuthukiswe ukwelashwa kwe-CML engazweli i-TKI, le mvume igcwalisa igebe elibalulekile lokwelashwa ku-T315I-mutant CML, futhi iphawula ingqopha-mlando ebonisa ukuthi i-Ascentage Pharma ingene ngempumelelo esigabeni sokuhweba.

Lokhu kugunyazwa kwe-olverembatinib kusekelwe emiphumeleni yocwaningo lweSigaba II esibalulekile - ucwaningo lwe-HQP1351CC201 kanye nocwaningo lwe-HQP1351CC202. Le miphumela ibonise ukuthi i-olverembatinib iyasebenza futhi ibekezelelwa kahle ezigulini ezine-CML-CP ne-CML-AP, futhi amathuba nokujula kwempendulo yomtholampilo kulindeleke ukuthi kukhule ngokuhamba kwesikhathi sokwelashwa.

I-CML iyisifo se-hematological samaseli amhlophe egazi. Ukwethulwa kwama-BCR-ABL TKIs kuthuthukise kakhulu ukuphathwa komtholampilo kwe-CML. Nokho, ukutholwa kokumelana nama-TKI kuseyinselelo enkulu ekwelashweni kwe-CML. Ukuguqulwa kwe-BCR-ABL kwe-tyrosine kinase kumelela indlela eyinhloko yokumelana nomuthi okutholiwe; I-T315I, okuwushintsho oluvame kakhulu olumelana nomuthi, kwenzeka cishe ku-25% weziguli ezine-CML engazweli emthini. Iziguli ezine-T315I-mutant CML azikwazi ukumelana nakho kokubili isizukulwane sokuqala nesesibili se-BCR-ABL inhibitors, yingakho zethula isidingo esiphuthumayo sezokwelapha esingahlangabeziwe sokwelashwa okusebenzayo.

Mayelana umbhali

I-avatar ka-Linda Hohnholz, umhleli we-eTN

ULinda Hohnholz, umhleli we-eTN

ULinda Hohnholz ubelokhu ebhala futhi ehlela izindatshana selokhu aqala ukusebenza. Usebenzise le nkanuko yokuzalwa ezindaweni ezifana neHawaii Pacific University, iChaminade University, iHawaii Children's Discovery Center, kanye neTravelNewsGroup manje.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...